347 Results

People

  1. Mauro
    Mauro
  2. Clarkson
    Clarkson
  3. Berman
    Berman
  4. O'Reilly
    O'Reilly
  5. Strife
    Strife
  6. Wisniewski
    Wisniewski
  7. Kernan
    Kernan
  8. Sawyers
    Sawyers
  9. Scheinberg
    Scheinberg
  10. Papadopoulos
    Papadopoulos

Groups

  1. Department of Medicine (242)
  2. Hematologic Malignancies, Division of (207)
  3. Center for Hematologic Malignancies (182)
  4. Adult Leukemia (117)
  5. Sloan Kettering Institute Faculty (108)
  6. GSK Faculty (106)
  7. Tow Center for Developmental Oncology (TCDO) (77)
  8. Molecular Pharmacology and Chemistry Program Faculty (71)
  9. Human Oncology and Pathogenesis Program (47)
  10. Pediatrics, Department of (46)
  1. "chronic myeloid leukemia"
Formats
  1. Journal Article (300)
  2. Meeting Abstract (18)
  3. Review (10)
  4. Conference Paper (8)
  5. Research Letter (6)
  6. Correspondence (2)
  7. Editorial (2)
  8. Guidelines (1)
Groups
  1. Department of Medicine (242)
  2. Hematologic Malignancies, Division of (207)
  3. Center for Hematologic Malignancies (182)
  4. Adult Leukemia (117)
  5. Sloan Kettering Institute Faculty (108)
  6. GSK Faculty (106)

More Groups

People
  1. Michael Mauro (56)
  2. Bayard Clarkson (40)
  3. Ellin Berman (24)
  4. Annabel Strife (20)
  5. Richard O'Reilly (20)
  6. David Wisniewski (18)

More People

Years
  1. 2025 (7)
  2. 2024 (16)
  3. 2023 (20)
  4. 2022 (13)
  5. 2021 (4)
  6. 2020 (8)

More Years

Publications
  1. Blood (29)
  2. Leukemia (23)
  3. Clinical Lymphoma, Myeloma and Leukemia (19)
  4. Biology of Blood and Marrow Transplantation (17)
  5. Bone Marrow Transplantation (15)
  6. Cancer Research (14)

More Publications

Publishers
  1. Elsevier Inc. (51)
  2. Nature Publishing Group (51)
  3. American Society of Hematology (33)
  4. American Association for Cancer Research (20)
  5. John Wiley & Sons (12)
  6. Springer (12)

More Publishers

Results (347)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia
    Journal Article

    Kantarjian, H. M.; Jabbour, E.; Deininger, M.; Abruzzese, E.; Apperley, J.; Cortes, J.; Chuah, C.; DeAngelo, D. J.; DiPersio, J.; Hochhaus, A.; more...
    American Journal of Hematology (2022)

    Fulltext@MSK | Save
  • Management of chronic myeloid leukemia in children and young adults
    Review

    Ford, M.; Mauro, M.; Aftandilian, C.; Sakamoto, K. M.; Hijiya, N.
    Current Hematologic Malignancy Reports (2022)

    Fulltext@MSK | Save
  • Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: Final results from the BFORE trial
    Journal Article

    Brümmendorf, T. H.; Cortes, J. E.; Milojkovic, D.; Gambacorti-Passerini, C.; Clark, R. E.; le Coutre, P.; Garcia-Gutierrez, V.; Chuah, C.; Kota, V.; Lipton, J. H.; more...
    Leukemia (2022)

    Fulltext@MSK | Save
  • A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase
    Review

    García-Gutiérrez, V.; Breccia, M.; Jabbour, E.; Mauro, M.; Cortes, J. E.
    Journal of Hematology & Oncology (2022)

    Fulltext@MSK | Save
  • Bioluminescent zebrafish transplantation model for drug discovery
    Journal Article

    Hason, M.; Jovicic, J.; Vonkova, I.; Bojic, M.; Simon-Vermot, T.; White, R. M.; Bartunek, P.
    Frontiers in Pharmacology (2022)

    Fulltext@MSK | Save
  • Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee
    Journal Article

    Januzzi, J. L.; Garasic, J. M.; Kasner, S. E.; McDonald, V.; Petrie, M. C.; Seltzer, J.; Mauro, M.; Croce, K.; Berman, E.; Deininger, M.; more...
    Journal of Hematology & Oncology (2022)

    Fulltext@MSK | Save
  • ASCEMBL phase 3 health-related quality of life (HRQL) comparison of asciminib and bosutinib for patients with chronic myelogenous leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosine kinase inhibitors (TKI)
    Meeting Abstract

    Mauro, M. J.; Boquimpani, C.; Rea, D.; Hochhaus, A.; Maheshwari, V. K.; Allepuz, A.; Patwardhan, P.; Wu, Y.; DeRosa, M.; Minami, Y.
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Health care resource utilization (HCRU) with asciminib and bosutinib among patients with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with ≥2 tyrosine kinase inhibitors (TKIs): Results from the multicenter, open-label phase 3 ASCEMBL trial
    Meeting Abstract

    Smith, B. D.; Cortes, J. E.; Rea, D.; Mauro, M. J.; Patwardhan, P.; Maegawa, R.; Zacker, C.; Corbin, R.; Keeping, S.; Sasaki, K.
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • AIM4CML trial in progress: A phase IIIb study of asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase (CML-CP) with and without T315I mutations
    Meeting Abstract

    Levy, M. Y.; Mauro, M. J.; Issa, G. C.; Andorsky, D.; Tomassetti, S.; Maegawa, R.; Shrestha, A.; Deininger, M.
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Long-term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome-positive leukemia resistant or intolerant to prior therapy
    Journal Article

    Cortes, J. E.; Kantarjian, H. M.; Mauro, M. J.; An, F.; Nick, S.; Leip, E.; Gambacorti-Passerini, C.; Brümmendorf, T. H.
    European Journal of Haematology (2021)

    Fulltext@MSK | Save